Clinical response framework for CLL using node, spleen/liver, marrow, blood count, lymphocyte, and progression features.
Calculated Interpretation
Stable Disease
Criteria for CR, PR, and PD are not met.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
Primary Use
Clinical response framework for CLL using node, spleen/liver, marrow, blood count, lymphocyte, and progression features.
Section 2
Formula & Logic
Clinical Inputs
Lymph node response
Categorical selection
Liver/spleen response
Categorical selection
Absolute lymphocyte count normalized
Binary clinical feature
Absolute lymphocyte count improved
Binary clinical feature
Hemoglobin meets CR threshold
Binary clinical feature
Platelets meet CR threshold
Binary clinical feature
Bone marrow fulfills CR threshold
Binary clinical feature
B-symptoms resolved
Binary clinical feature
B-symptoms worsened
Binary clinical feature
New lesion or Richter-type progression
Binary clinical feature
Interpretive Logic
Progressive disease is driven by new lesions or clinical worsening.
CR requires normalized counts, resolved disease burden, and marrow remission.
CRi captures near-CR without full marrow clearance.
PR requires meaningful improvement without full CR.
Section 3
Pearls/Pitfalls
Result Bands
CR
Complete response
CRi
CR with incomplete marrow recovery/confirmation
PR
Partial response
SD/PD
Stable or progressive disease
Section 4
Next Steps
Suggested Next Steps
01
Interpret the result in the full disease-specific clinical context.
02
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.
Section 5
Evidence Appraisal
Evidence Base
Clinical response framework for CLL using node, spleen/liver, marrow, blood count, lymphocyte, and progression features.
OpiCalc Medical Oncology Module • Haematological Malignancies. 2026;Logic implemented from widely used contemporary oncology classification, prognostic, and response-assessment frameworks.
Section 6
Literature
Context
iwCLL 2018 Response is included in the oncology module as a structured decision-support tool for haematological malignancies workflows.
